Sunshine Biopharma (SBFMW) EBT Margin (2015 - 2026)

Sunshine Biopharma has reported EBT Margin for 10 years, with the latest figure at 15.38% in Q1 2026.

• For the quarter ending Q1 2026, EBT Margin fell 167.0% year-over-year to 15.38%; the trailing twelve-month figure through Mar 2026 stood at 16.84% (down 2005.0% YoY), and the FY2025 full-year result was 16.4%, down 1962.0% from the prior year.
• EBT Margin for Q1 2026 stood at 15.38%, up from 20.2% in the prior quarter.
• The five-year high for EBT Margin was 43.81% in Q4 2024, with the low at 1097.09% in Q3 2022.
• Historically, EBT Margin has averaged 188.31% across 5 years, with a median of 15.38% in 2026.
• The largest YoY upside for EBT Margin was 1443245 bps in 2022 against a maximum downside of 137462 bps in 2022.
• Sunshine Biopharma's EBT Margin stood at 590.86% in 2022, then surged by 98 bps to 13.41% in 2023, then surged by 427 bps to 43.81% in 2024, then sank by 146 bps to 20.2% in 2025, then climbed by 24 bps to 15.38% in 2026.
• The last three EBT Margin figures came in at 15.38% (Q1 2026), 20.2% (Q4 2025), and 10.84% (Q3 2025), per Business Quant data.